4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Monday, March 3rd. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.92) per share for the quarter. HC Wainwright has a "Buy" rating and a $36.00 price objective on the stock. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics' Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.93) EPS, Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.72) EPS, FY2026 earnings at ($4.00) EPS, FY2027 earnings at ($4.32) EPS, FY2028 earnings at ($4.07) EPS and FY2029 earnings at ($2.80) EPS.
4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10).
FDMT has been the subject of several other reports. Weiss Ratings reissued a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Friday. BMO Capital Markets downgraded 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Leerink Partners cut their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an "outperform" rating on the stock in a research note on Monday, January 13th. Bank of America decreased their price target on shares of 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Monday. Finally, Morgan Stanley lowered their price target on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an "underweight" rating for the company in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $30.63.
Read Our Latest Stock Report on FDMT
4D Molecular Therapeutics Stock Performance
Shares of NASDAQ:FDMT traded down $0.18 during trading on Thursday, hitting $3.89. The company's stock had a trading volume of 829,356 shares, compared to its average volume of 799,182. The company has a market capitalization of $180.11 million, a PE ratio of -1.36 and a beta of 2.83. 4D Molecular Therapeutics has a fifty-two week low of $3.85 and a fifty-two week high of $36.25. The business has a 50 day moving average price of $5.05 and a two-hundred day moving average price of $8.17.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of FDMT. Proficio Capital Partners LLC purchased a new stake in 4D Molecular Therapeutics in the third quarter valued at $108,000. Privium Fund Management B.V. increased its position in shares of 4D Molecular Therapeutics by 146.3% during the third quarter. Privium Fund Management B.V. now owns 98,500 shares of the company's stock worth $1,065,000 after purchasing an additional 58,500 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at about $295,000. Intech Investment Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at about $268,000. Finally, Algert Global LLC grew its stake in 4D Molecular Therapeutics by 342.7% during the 3rd quarter. Algert Global LLC now owns 73,436 shares of the company's stock worth $794,000 after buying an additional 56,848 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company's stock.
About 4D Molecular Therapeutics
(
Get Free Report)
4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.
Read More
Before you consider 4D Molecular Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.
While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
